Pyoderma gangrenosum: a rare cause of breast ulceration.

Breast ulceration is an alarming sign for clinicians and places a significant physical and psychological burden on the patient. We report a rare presentation of pyoderma gangrenosum of the breast in a patient known to have ulcerative colitis but no active underlying disease process and no history of breast tissue trauma. This case report with literature review highlights the importance of considering pyoderma gangrenosum as a differential diagnosis in breast ulcers.

Is the Stryker Revolution mixing system fit for purpose? Reliability and a micro-CT assessment of cement porosity.

The Stryker Revolution(TM) is a new mixing system that employs a high vacuum and a motorised mixing spatula in an effort to reduce cement porosity. We have compared Revolution(TM) with Depuy Cemvac(®), in terms of system reliability and cement porosity. Standardised Simplex P(®) and SmartSet(®) HV cement samples were produced using both mixing systems and analysed using a micro-CT scanner. The overall porosity, number and volume of voids were measured. Void analysis was subdivided into macro-pores (>0.5 mm3) and micro-pores (0.0005-0.5 mm3). Both systems were easy to use and no breakages were encountered. There was no significant difference in overall porosity between Revolution(TM) and Cemvac(®). Revolution(TM) produced over a five-fold decrease in average macro-pore size with medium viscosity cement (p=0.02), but produced a greater number of micro-pores (p<0.01). SmartSet(®) HV specimens had a higher porosity compared to Simplex P(®). This study demonstrated that the Revolution(TM) system was reliable and reduced porosity at least as effectively as the established Cemvac(®) system. The Revolution(TM) produced a greater number of smaller pores and further testing is required to establish if this results in a significant mechanical benefit.

Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.

We investigated the incidence of AMS amongst a general population of trekkers on Mount Kilimanjaro, using the Lake Louise consensus scoring system (LLS). Additionally we examined the effect of prophylactic acetazolamide and different ascent profiles. Climbers on 3 different ascent itineraries were recruited. At 2743 m we recruited 177 participants (mean age 31, range [18-71]) who completed LLS together with an epidemiological questionnaire. At 4730 m participants (n=189, male=108, female=68, mean age 33, range [1871]) completed LLS, 136 of whom had been followed up from 2730 m. At 2743 m, 3% (5/177) of climbers were AMS positive, and 47% (89/189) of climbers from all itineraries were AMS positive at 4730 m. Of climbers attempting the Marangu itineraries, 33% (45/136) were taking acetazolamide. This group had a similar rate of AMS and no statistical difference in severity of LLS when compared with those not taking prophylactic drugs. We also did not demonstrate a difference between the incidence of AMS in climbers who did or did not take a rest day at 3700 m. However, there was a significant reduction in the incidence of AMS amongst pre-acclimatized subjects. Consistent with previous work, we found that the rate of AMS on Mount Kilimanjaro is high. Furthermore, at these fast ascent rates, there was no evidence of a protective effect of acetazolamide or a single rest day. There is a need to increase public awareness of the risks of altitude sickness and we advocate a pragmatic "golden rules" approach (http://www.altitude.org/altitude_sickness.php).